Literature DB >> 11812770

Glycogen synthase kinase-3beta is complexed with tau protein in brain microtubules.

Wei Sun1, Hamid Y Qureshi, Patrick W Cafferty, Kazuya Sobue, Alka Agarwal-Mawal, Katherine D Neufield, Hemant K Paudel.   

Abstract

In Alzheimer's disease, microtubule-associated protein tau is hyperphosphorylated by an unknown mechanism and is aggregated into paired helical filaments. Hyperphosphorylation causes loss of tau function, microtubule instability, and neurodegeneration. Glycogen synthase kinase-3beta (GSK3beta) has been implicated in the phosphorylation of tau in normal and Alzheimer's disease brain. The molecular mechanism of GSK3beta-tau interaction has not been clarified. In this study, we find that when microtubules are disassembled, microtubule-associated GSK3beta dissociates from microtubules. From a gel filtration column, the dissociated GSK3beta elutes as an approximately 400-kDa complex. When fractions containing the approximately 400-kDa complex are chromatographed through an anti-GSK3beta immunoaffinity column, tau co-elutes with GSK3beta. From fractions containing the approximately 400-kDa complex, both tau and GSK3beta co-immunoprecipitate with each other. GSK3beta binds to nonphosphorylated tau, and the GSK3beta-binding region is located within the N-terminal projection domain of tau. In vitro, GSK3beta associates with microtubules only in the presence of tau. From brain extract, approximately 6-fold more GSK3beta co-immunoprecipitates with tau than GSK3alpha. These data indicate that, in brain, GSK3beta is bound to tau within a approximately 400-kDa microtubule-associated complex, and GSK3beta associates with microtubules via tau.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11812770     DOI: 10.1074/jbc.M107182200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  38 in total

Review 1.  Tau-targeted treatment strategies in Alzheimer's disease.

Authors:  Jürgen Götz; Arne Ittner; Lars M Ittner
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

2.  Genetically augmenting Abeta42 levels in skeletal muscle exacerbates inclusion body myositis-like pathology and motor deficits in transgenic mice.

Authors:  Masashi Kitazawa; Kim N Green; Antonella Caccamo; Frank M LaFerla
Journal:  Am J Pathol       Date:  2006-06       Impact factor: 4.307

3.  The amino terminus of tau inhibits kinesin-dependent axonal transport: implications for filament toxicity.

Authors:  Nichole E LaPointe; Gerardo Morfini; Gustavo Pigino; Irina N Gaisina; Alan P Kozikowski; Lester I Binder; Scott T Brady
Journal:  J Neurosci Res       Date:  2009-02       Impact factor: 4.164

4.  DYRK1B regulates Hedgehog-induced microtubule acetylation.

Authors:  Rajeev Singh; Philipp Simon Holz; Katrin Roth; Anna Hupfer; Wolfgang Meissner; Rolf Müller; Malte Buchholz; Thomas M Gress; Hans-Peter Elsässer; Ralf Jacob; Matthias Lauth
Journal:  Cell Mol Life Sci       Date:  2018-10-13       Impact factor: 9.261

5.  Pharmacologic blockade of 12/15-lipoxygenase ameliorates memory deficits, Aβ and tau neuropathology in the triple-transgenic mice.

Authors:  J Chu; J-G Li; P F Giannopoulos; B E Blass; W Childers; M Abou-Gharbia; D Praticò
Journal:  Mol Psychiatry       Date:  2015-01-06       Impact factor: 15.992

6.  Pathogenic forms of tau inhibit kinesin-dependent axonal transport through a mechanism involving activation of axonal phosphotransferases.

Authors:  Nicholas M Kanaan; Gerardo A Morfini; Nichole E LaPointe; Gustavo F Pigino; Kristina R Patterson; Yuyu Song; Athena Andreadis; Yifan Fu; Scott T Brady; Lester I Binder
Journal:  J Neurosci       Date:  2011-07-06       Impact factor: 6.167

7.  Early growth response 1 (Egr-1) regulates phosphorylation of microtubule-associated protein tau in mammalian brain.

Authors:  Yifan Lu; Tong Li; Hamid Y Qureshi; Dong Han; Hemant K Paudel
Journal:  J Biol Chem       Date:  2011-04-13       Impact factor: 5.157

8.  Parkinsonian neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and alpha-synuclein mutations promote Tau protein phosphorylation at Ser262 and destabilize microtubule cytoskeleton in vitro.

Authors:  Hamid Y Qureshi; Hemant K Paudel
Journal:  J Biol Chem       Date:  2010-12-02       Impact factor: 5.157

9.  5-Lipoxygenase gene transfer worsens memory, amyloid, and tau brain pathologies in a mouse model of Alzheimer disease.

Authors:  Jin Chu; Phillip F Giannopoulos; Carolina Ceballos-Diaz; Todd E Golde; Domenico Praticò
Journal:  Ann Neurol       Date:  2012-09       Impact factor: 10.422

10.  The influence of 5-lipoxygenase on Alzheimer's disease-related tau pathology: in vivo and in vitro evidence.

Authors:  Jin Chu; Jian-Guo Li; Carolina Ceballos-Diaz; Todd Golde; Domenico Praticò
Journal:  Biol Psychiatry       Date:  2013-01-23       Impact factor: 13.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.